CardioFocus to Acquire Galvanize Therapeutics’ Electrophysiology Technology Division
Shots:
- The acquisition includes CENTAURI System pulsed electric field generator, the QuickShot catheter ablation system and an IP portfolio incl. license for foundational patent families in pulsed electric field therapies, ownership of electrophysiology and pulsed-field patent families, and an extensive knowledge of waveform and algorithms, aimed at minimizing microbubbles and muscle stimulation
- The CENTAURI System disrupts aberrant electrical signals causing atrial fibrillation in the heart. It uses an exclusive waveform making it compatible with various focal ablation catheters and mapping systems
- The QuickShot system, incorporating a large area focal catheter, is under development and its human trial is anticipated in 2024
Ref: PR Newswire | Image: Galvanize Therapeutics
Related News:- Medtronic Expands its Collaboration with Cosmo Pharmaceuticals to transform endoscopy by utilizing advanced AI Technology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
